Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility

Acta Pharmacologica Sinica

Volumn 32, Issue 1, 2011, Pages 108-115

  Duan, Rui Ling ^a   Sun, Xun ^a   Liu, Jie ^a   Gong, Tao ^a   Zhang, Zhi Rong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

bile salts; mixed micelles; phospholipid complex; silybin; solubility

Indexed keywords

BILE SALT; LIVER PROTECTIVE AGENT; SILIBININ N METHYLGLUCAMINE; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; IN VIVO STUDY; IONIC STRENGTH; MALE; MAXIMUM PLASMA CONCENTRATION; MICELLE; NONHUMAN; PARTICLE SIZE; RAT; SCANNING ELECTRON MICROSCOPY; TEMPERATURE SENSITIVITY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; ANTIOXIDANTS; BILE ACIDS AND SALTS; CALORIMETRY, DIFFERENTIAL SCANNING; INFUSIONS, INTRAVENOUS; MICELLES; MILK THISTLE; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; RATS; SILYMARIN; SOLUBILITY;

EID: 78651077286     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.192     Document Type: Article

References (38)

1. Dressman J, Reppas C. Drug solubility: How to measure it, how to improve it. Adv Drug Deliver Rev 2007; 59: 531-2.
2. Serajuddin, Abu TM. Salt formation to improve drug solubility. Adv Drug Deliver Rev 2007; 59: 603-16.
3. Blagden N, Matas M de, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliver Rev 2007; 59: 617-30.
4. Kesisoglou F, Panmai S, Wu Y. Nanosizing - Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliver Rev 2007; 59: 631-44.
5. Hauss DJ. Oral lipid-based formulations. Adv Drug Deliver Rev 2007; 59: 667-76.
6. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliver Rev 2007; 59: 645-66.
7. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Deliver Rev 2007; 59: 677-94.
8. Gao Y, Li LB, Zhai G. Preparation and characterization of Pluronic/ TPGS mixed micelles for solubilization of camptothecin. Colloid Surface B 2008; 64: 194-9.
9. Kvasnicka F, Biba B, Sevcik R, Voldrich M, Kratka J. Analysis of the active components of silymarin. J Chromatogr A 2003; 990: 239-45.
10. Tedesco D, Tava A, Galletti S, Tameni M, Varisco G, Costa A, et al. Effects of silymarin, a natural hepatoprotector, in periparturient dairy cows. J Dairy Sci 2004; 87: 2239-47.
11. Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Di Manzano C, et al. Silybin is a direct antifibrogenic and antiinflammatory agent: Cellular and molecular mechanisms. Digest Liver Dis 2008; 40: A127.
12. Wu JW, Lin LC, Hung SC, Chi CW, Tsai TH. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharmaceut Biomed 2007; 45: 635-41.
13. Lasonder E, Weringa WD. An NMR and DSC study of the interaction of phospholipids vesicles with some anti-inflammatory agents. J Colloid Interf Sci 1990; 139: 469-78.
14. Morazzoni P, Magistretti MJ, Giachetti C, Zanolo G. Comparative bioavailability of silipide, a new flavanolignan complex, in rats. Euro J Drug Metab Pharmacokinet 1992; 17: 39-44.
15. Xiao YY, Song YM, Chen ZP, Ping QN. The preparation of silybin - phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm 2006; 307: 77-82.
16. Chen W, Xia H, Wu W. Optimized preparation of silymarin dripping pills by a central composite design-response surface method. Chin Trad Herb Drug 2005; 36: 679-83.
17. Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by selfmicroemulsifying drug delivery system. Eur J Pharm Biopharm 2006; 63: 288-94.
18. Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM. A mixed micellar formulation suitable for the parenteral administration of taxol. Pharm Res 1994; 11: 206-12.
19. Hammad MA, Müller BW. Increasing drug solubility by of bile saltphosphatidylcholine- based mixed micelles. Eur J Pharm Biopharm 1998; 46: 361-7.
20. Hammad MA, Müller BW. Solubility and stability of tetrazepam in mixed micelles. Eur J Pharm Sci 1998; 7: 49-55.
21. Steffen H. Prinzip Mischmizelle. Die Gallensäure-Lecithin- Mischmizllen als Trägersystem schwer wasserlösliche Wirkstoffe. Roche Magazine 1984; 20: 2-9.
22. Teelmann K, Schläppi B, Schüpbach M, Kistler A. Preclinical safety evaluation of intravenously administered mixed micelles. Arzneimittelforschung 1984; 34: 1517-23.
23. Schurtenberger P, Mazer N, Känzig W. Miceller vesicle transition in aqueous solution of bile salt and lecithin. J Phys Chem 1985; 89: 1042-9.
24. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin- phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007; 330: 155-63.
25. Komatsu H, Kitajima A, Okada S. Pharmaceutical characterzation of commercially available intravenous fat emulsions: Estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy. Chem Pharm Bull 1995; 43: 1412-5.
26. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-77.
27. Müller RH, Rühl D, Runge SA. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm 1996; 144: 115-21.
28. Liu J, Gong T, Wang CG, Zhong ZR, Zhang ZR. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization. Int J Pharm 2007; 340: 153-62.
29. Horejsová M, Urban J. The effect of polyene phosphatidylcholine (Essentiale forte) in the treatment of liver steatosis and ultrasound findings-preliminary study. Cas Lek Cesk 1994; 133: 366-9.
30. Hwang SB, Shen TY. Membrane effects of anti-inflammatory agents. 2. Interaction of nonsteroidal anti-inflammatory drugs with liposome and purple membranes. J Med Chem 1981; 24: 1202-12.
31. Venema FR, Weringa WD. The interactions of phospholipid vesicles with some anti-inflammatory agents. J Colloid Interf Sci 1988; 125: 484-500.
32. Flockhart BD. The effect of temperature on the critical micelle concentration of some paraffin-chain salt. J Colloid Sci 1961; 16: 484-92.
33. Alkan-Onyuksel H, Son K. Mixed micelles as proliposomes for the solubilization of tenposide. Pharm Res 1992; 9: 1556-62.
34. Carey MC, Small DM. The characteristics of mixed micellar solutions with particular reference to bile. Amer J Med 1970; 49: 590-608.
35. Mazer NA, Benedek GB, Carey MC. Quasielastic light-scattering studies of aqueous biliary lipid systems. Mixed micelle formation in bile salt-lecithin solutions. Biochem 1980; 19: 601-15.
36. Dongowski G, Fritzscb B, Giessler J, Härtl A, Kuhlmann O, Neuber RHH. The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits. Eur J Pharm Biopharm 2005; 60: 147-51.
37. Ploema FGJ, Tucker JJ, Crommelin DJA. The role of bile salts in the intestinal absorption of drugs. Acta Pharm Technol 1990; 36: 43-52.
38. Yu JN, Zhu Y, Wang L, Peng M, Tong SS, Cao X, et al. Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles. Acta Pharmacol Sin 2010; 31: 759-64.